Home › Research › Biomarkers
Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 Treatment
Hey JA, Geerts H, Schaefer JF, Short SM, Graaf P, Abushakra S, Power A, Tolar M et al.. Research Square, 2026-08-24
Topic: Drug trials: efficacy and safety
Apolipoprotein E4 (APOE4) is a major risk factor for Alzheimer’s disease (AD). Valiltramiprosate/ALZ-801, an oral inhibitor of β-amyloid (Aβ) oligomer formation, was evaluated in APOE4/4 subjects with early AD in the APOLLOE4 Phase 3 trial. We used quantitative systems pharmacology (QSP) to characterize AD trajectories by APOE genotype and assess the effects of valiltramiprosate treatment. An existing QSP model of Aβ aggregation in AD was extended to incorporate APOE4 genotypes and a hippocampal atrophy readout based on hippocampal volume (HV), calibrated with observational and interventional data from lecanemab and donanemab studies. Valiltramiprosate’s anti-Aβ oligomer and APOE4 structure-corrector pharmacology was simulated over 2–10 years of treatment. Model predictions were validated against the plasma Aβ42/Aβ40 results from the valiltramiprosate Phase 2 study and HV outcomes from APOLLOE4. APOE genotype altered the natural trajectory of Aβ aggregation, with APOE4/4 associated with earlier onset and faster pathology, consistent with a gene-dose effect (APOE4/4 > > APOE3/4 > APOE3/3). Valiltramiprosate 265 mg administered orally twice daily increased the plasma Aβ42/Aβ40 ratio and CSF Aβ42, reduced oligomers and protofibrils, and had minimal effects on plaques. Long-term modeled treatment with valiltramiprosate prevented aggregation and shifted Aβ toward monomers. The QSP analysis was supported by Phase 2 plasma Aβ42/Aβ40 findings and was consistent with Phase 3 results, indicating greater brain volumetric benefit in APOE4/4 subjects with Mild Cognitive Impairment (MCI) than in those with mild AD. The magnitude of valiltramiprosate’s effects depended on age, genotype, and disease stage, and was substantially differentiated from anti-amyloid antibody monotherapy with lecanemab or donanemab. A measurable APOE4 structure-corrector effect was observed in APOE4 carriers; however, anti-Aβ oligomer pharmacology accounted for most of valiltramiprosate’s effects on fluid biomarkers and hippocampal atrophy trajectories over time in AD. This enhanced Aβ aggregation and HV QSP model enables evaluation of therapeutic interventions across APOE genotypes. These findings support greater benefit of oral valiltramiprosate in early AD, particularly MCI, and suggest potential utility as preventive therapy in presymptomatic AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hey, J. A., Geerts, H., Schaefer, J. F., Short, S. M., Graaf, P., Abushakra, S., et al. (2026). Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 Treatment. Research Square. https://doi.org/10.21203/rs.3.rs-10570608/v1
Vancouver
Hey JA, Geerts H, Schaefer JF, Short SM, Graaf P, Abushakra S, et al. Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 Treatment. Research Square. 2026. doi:10.21203/rs.3.rs-10570608/v1.
BibTeX
@article{hey2026-a02492d7,
author = {Hey, J. A. and Geerts, H. and Schaefer, J. F. and Short, S. M. and Graaf, P. and Abushakra, S. and Power, A. and Tolar, M. and others},
title = {{Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer’s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 Treatment}},
journal = {Research Square},
year = {2026},
doi = {10.21203/rs.3.rs-10570608/v1},
url = {https://doi.org/10.21203/rs.3.rs-10570608/v1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Model predictions were validated against the plasma Aβ42/Aβ40 results from the valiltramiprosate Phase 2 study and HV outcomes from APOLLOE4.
- APOE genotype altered the natural trajectory of Aβ aggregation, with APOE4/4 associated with earlier onset and faster pathology, consistent with a gene-dose effect (APOE4/4 > > APOE3/4 > APOE3/3).
- The QSP analysis was supported by Phase 2 plasma Aβ42/Aβ40 findings and was consistent with Phase 3 results, indicating greater brain volumetric benefit in APOE4/4 subjects with Mild Cognitive Impairment (MCI) than in those with mild AD.
- These findings support greater benefit of oral valiltramiprosate in early AD, particularly MCI, and suggest potential utility as preventive therapy in presymptomatic AD.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designclinical trial
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 21 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 13 of the 62 points we could judge it on, which is 21 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (Research Square) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 13 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 13 of the 62 points we could judge it on is 21 out of 100. |
| Total | 21 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Biomarkers
Also tagged “apoe2”
266 studies in the library carry the topic tag “apoe2”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 266 tagged studies.